Home : DrugWatch : Plavix : Wikipedia : Sanofi-Aventis

Wikipedia - Sanofi-Aventis

Sanofi-Aventis S.A.
Type Société Anonyme (Euronext: SAN, NYSE: SNY, LSE: 0I42, FWB: SNW)
Industry Pharmaceuticals
Founded 20 August 2004 (by acquisition)
Headquarters Paris, France
Key people Chris Viehbacher (CEO), Jean-François Dehecq (Chairman of the board)
Products Prescription and over-the-counter drugs for thrombosis, cardiovascular disease, diabetes, central nervous system disorders, oncology and internal medicine, vaccines (list...)
Revenue €29.31 billion (2009)[1]
Operating income ? €6.366 billion (2009)[1]
Profit ? €5.265 billion (2009)[1]
Employees 104,870 (2009)[1]
Subsidiaries Sanofi Pasteur
Website en.sanofi-aventis.com

Sanofi-Aventis (Euronext: SAN, NYSE: SNY), headquartered in Paris, France, is a multinational pharmaceutical company, the world's fourth-largest by prescription sales.[2][3] Sanofi-Aventis engages in the research and development, manufacturing and marketing of pharmaceutical products for sale principally in the prescription market, but the firm also develops over-the-counter medication. Sanofi-Aventis covers 7 major therapeutic areas: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis and vaccines (it is the world's largest producer of the latter through its subsidiary Sanofi Pasteur).[4] The company is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).[5]

Contents

[edit] History

[edit] Sanofi-Aventis

Question book-new.svg
 This article needs additional citations for verification.
Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (April 2009)

Sanofi-Aventis was formed in 2004 when Sanofi-Synthélabo acquired Aventis. In early 2004, Sanofi-Synthélabo made a hostile takeover bid worth €47.8 bn for Aventis. Initially, Aventis rejected the bid because it felt that the bid offered inferior value based on the company's share value. The three-month takeover battle concluded when Sanofi-Synthélabo launched a friendly bid of €54.5 bn in place of the previously rejected hostile bid. French government intervention also played an active role. The French government, desiring what they called a "local solution", put heavy pressure on Sanofi-Synthélabo to raise its bid for Aventis after it became known that Novartis, a Swiss pharmaceutical company, was in the running.

[edit] Sanofi-Synthélabo

Sanofi-Synthélabo was formed in 1999 when Sanofi (former subsidiary of Total) merged with Synthélabo (former subsidiary of L'Oréal). The merged company was based in Paris, France.

[edit] Aventis

Main article: Aventis

Aventis was formed in 1999 when French company Rhône-Poulenc S.A. merged with the German corporation Hoechst Marion Roussel, which itself was formed from the 1995 merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The merged company was based in Schiltigheim, near Strasbourg, France.

[edit] Business

[edit] Products

Pharmaceuticals produced by Sanofi-Aventis include Lovenox/Clexane for thrombosis (its biggest seller in 2008),[6] Plavix/Iscover for atherothrombosis, Apidra and Lantus for diabetes, Taxotere for breast, lung and prostate cancer, Eloxatin for colorectal cancer, Stilnox/Ambien/Ambien CR/Myslee/Zolfresh/Zolt/Stilnoct for insomnia, Copaxone for multiple sclerosis, Aprovel/Avapro/Karvea and Delix/Tritace/Triatec for hypertension, Allegra/Telfast and Nasacort for allergic rhinitis, Menactra for meningitis, Xatral for benign prostatic hyperplasia, Actonel for osteoporosis and Paget’s disease and Depakine and Depakote for epilepsy, Biprofened for pain.

[edit] Management

Dehecq was the General Manager of Sanofi from its creation in 1973 until 2007.

[edit] Stockholders

As of 31 January 2010:[1]

  • Breakdown of share ownership: 6.96% by Total, 8.97% by L'Oréal, 0.71% treasury shares and 1.37% employees. The remaining 77.86% are publicly traded.
  • Voting rights distribution: 11.76% to Total, 15.36% to L'Oréal, 2.10% to employees, and 70.78% to the public.

[edit] Collaborative research

In addition to internal research and development activities Sanofi-Aventis is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.[9][10] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.[11]

In June 2010, Sanofi-aventis and the Charite University of Berlin signed a cooperation agreement for the research and development of medicines and therapies.[12]

[edit] Aventis Foundation

The Aventis Foundation [13], a German charitable trust, was established in 1996 as the Hoechst Foundation with an endowment of €50 million. In 2000, the foundation was renamed the Aventis Foundation. Its aim is to promote music, theater, art, literature, higher education and healthcare research.

[edit] See also

[edit] References

  1. ^ a b c d e "Annual Report 2009". Sanofi-Aventis. http://en.sanofi-aventis.com/binaries/20F_2009_tcm28-27683.pdf. Retrieved 2010-03-21. 
  2. ^ IMS Health 2008
  3. ^ Keller, Greg (10 September 2008). "Sanofi names Viehbacher as new CEO". Associated Press (USA Today). http://www.usatoday.com/money/economy/2008-09-10-4035378426_x.htm. Retrieved 2009-04-19. 
  4. ^ "Sanofi-Aventis to sign deal to build flu vaccine plant in China - source". AFX News (Forbes). 23 November 2007. http://www.forbes.com/feeds/afx/2007/11/23/afx4368351.html. Retrieved 2009-04-19. 
  5. ^ "The Pharmaceutical Industry in Figures - 2008 Edition". European Federation of Pharmaceutical Industries and Associations (EFPIA). pp. 49. http://www.efpia.eu/content/default.asp?PageID=559&DocID=4883. Retrieved 2008-08-25. 
  6. ^ "Annual Review 2008". Sanofi-Aventis. http://en.sanofi-aventis.com/binaries/Sanofi_RA_EN_tcm28-24842.pdf. Retrieved 2009-04-19. 
  7. ^ Sanofi-Aventis splits chairman-CEO job; Dehecq stays chairman, Le Fur named CEO 15.12.2006
  8. ^ Chris Viehbacher wird Nachfolger von Sanofi-Aventis-Chef Le Fur 10.09.2008
  9. ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
  10. ^ "InnoMed PredTox Member Organizations". http://www.innomed-predtox.com/consortium/members/. Retrieved 2008-08-25. 
  11. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. http://imi.europa.eu/docs/calls01_en.zip. Retrieved 2008-08-25. 
  12. ^ Sanofi-aventis, Charite University Sign Cooperation Agreement News article from InfoGrok.
  13. ^ http://www.aventis-foundation.org/

[edit] External links

Factory 1b.svg Companies portal
v • d • e
France CAC 40 companies of France
Retrieved from "http://en.wikipedia.org/wiki/Sanofi-Aventis"

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Sanofi-Aventis".

Need A Plavix Attorney?

First Name Last Name Email Address State
Has Your Health Been Negatively Affected?

Please Describe the Injury

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Looking for a Plavix attorney in Washington, DC? Get in touch with one of our Plavix attorneys in Washington, DC now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Plavix Case - Submit Your Information Below

Do you need legal assistance with your Plavix case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!

* Indicates Required Fields

First name *
Last name *
Email Address *
Phone Number *
()  -

State *
Legal Issue * DrugWatch: Plavix Change
Was There an Injury?
Please Describe The Injury

DISCLAIMER and STATEMENT OF NON-CONFIDENTIALITY

By submitting this form, you agree that completing the above is not intended to create an attorney-client relationship.

Disclosure

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website [more...]

Legal WebTV Network LLC, LegalView.com, and LegalWebMedia.com are group advertising sponsored by the attorneys identified here. It is not a lawyer referral service. If you submit information on this website, LegalWebMedia.com will submit your information to the law firms that pay for this group advertising and to respond to your requests for information concerning legal services in their assigned local areas. If there is no sponsoring firm in your state, your inquiry will be submitted to one of the sponsoring law firms on a predetermined, rotating basis. If the sponsoring law firm accepts your case, it will associate with licensed attorneys practicing in your state, if required; the sponsoring law firm may also contact other law firms to see if they may be able to assist.

The information provided by the LegalView.com and LegalWebMedia.com websites is for advertising and informational purposes and should not be considered as legal advice from the sponsoring attorneys. The websites contain general information and may not reflect current legal developments, verdicts, or settlements. LegalView.com contains information created by others or supplied through open forums; the sponsoring law firms are not responsible for the accuracy of this information. Any person viewing or receiving information from these websites should not act or refrain from acting on the basis of any such information without first seeking appropriate legal advice from an attorney in your area. Legal WebTV Network, LLC expressly disclaims any liability with respect to actions taken or not taken by the recipient based on any or all of the information or contents contained in these websites.

Any information sent to Legal WebTV Network LLC through this website is done using standard Web encryption techology. LegalView.com will exercise all reasonable care, within technological limits, to protect the confidentiality of any information submitted via Internet e-mail or through this website. By accessing this website, you may be seeking an attorney to represent you or legal advice. However, none of the sponsoring attorneys represent you yet.

The choice of a lawyer is an important decision and should not be based solely upon advertisements.

Any transmission of information, whether via Internet e-mail or through the website, is solely for evaluation purposes by the sponsoring law firms and their associates. The transmission of any information to any attorney sponsoring advertising on LegalView.com or LegalWebMedia.com does not create an attorney-client relationship between the sender and any recipient. An attorney-client relationship can only be created by a written, signed-fee agreement entered into with an attorney. The sponsoring attorneys will treat your information as a confidential communication for the purpose of obtaining legal services or legal advice.

For more information about the sponsoring law firms, please click here.
This form is secure and encrypted. More information about secure forms and your privacy here.